{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:58:30Z","timestamp":1787763510461,"version":"build-2784847793"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Surgery"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.ijsu.2019.03.004","type":"journal-article","created":{"date-parts":[[2019,3,17]],"date-time":"2019-03-17T01:41:09Z","timestamp":1552786869000},"page":"1-11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":114,"special_numbering":"C","title":["Teriparatide versus bisphosphonates for treatment of postmenopausal osteoporosis: A meta-analysis"],"prefix":"10.1097","volume":"66","author":[{"given":"Fei","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caihong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinping","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"15","key":"10.1016\/j.ijsu.2019.03.004_bib1","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1001\/jama.2017.21640","article-title":"Vitamin D, calcium, or combined supplementation for the primary prevention of fractures in community-dwelling adults: evidence report and systematic review for the US preventive services task force","volume":"319","author":"Kahwati","year":"2018","journal-title":"Jama"},{"issue":"9","key":"10.1016\/j.ijsu.2019.03.004_bib2","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1002\/jbmr.3437","article-title":"How can we improve osteoporosis care: a systematic review and meta-analysis of the efficacy of quality improvement strategies for osteoporosis","volume":"33","author":"Nayak","year":"2018","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.ijsu.2019.03.004_bib3","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/13697137.2018.1433655","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis: a meta-analysis of randomized controlled trials","volume":"21","author":"Liu","year":"2018","journal-title":"Climacteric"},{"issue":"1","key":"10.1016\/j.ijsu.2019.03.004_bib4","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12872-018-0758-8","article-title":"A population-based screening study for cardiovascular diseases and diabetes in Danish postmenopausal women: acceptability and prevalence","volume":"18","author":"Dahl","year":"2018","journal-title":"BMC Cardiovasc. Disord."},{"issue":"6","key":"10.1016\/j.ijsu.2019.03.004_bib5","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.1002\/jcb.26550","article-title":"A network meta-analysis on the short-term efficacy and adverse events of different anti-osteoporosis drugs for the treatment of postmenopausal osteoporosis","volume":"119","author":"Liu","year":"2018","journal-title":"J. Cell. Biochem."},{"issue":"7","key":"10.1016\/j.ijsu.2019.03.004_bib6","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1302\/2046-3758.67.BJR-2016-0292.R1","article-title":"The efficacy and safety of vertebral fracture prevention therapies in post-menopausal osteoporosis treatment: which therapies work best? a network meta-analysis","volume":"6","author":"Wang","year":"2017","journal-title":"Bone Joint Res"},{"issue":"78","key":"10.1016\/j.ijsu.2019.03.004_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta20780","article-title":"A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures","volume":"20","author":"Davis","year":"2016","journal-title":"Health Technol. Assess."},{"issue":"5","key":"10.1016\/j.ijsu.2019.03.004_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128032","article-title":"Comparison of bone mineral density in lumbar spine and fracture rate among eight drugs in treatments of osteoporosis in men: a network meta-analysis","volume":"10","author":"Chen","year":"2015","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.ijsu.2019.03.004_bib9","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1097\/GME.0000000000000466","article-title":"Indirect comparison of teriparatide, denosumab, and oral bisphosphonates for the prevention of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis","volume":"22","author":"Zhang","year":"2015","journal-title":"Menopause"},{"issue":"3","key":"10.1016\/j.ijsu.2019.03.004_bib10","doi-asserted-by":"crossref","first-page":"E146","DOI":"10.25011\/cim.v40i3.28394","article-title":"Head-to-head comparisons of bisphosphonates and teriparatide in osteoporosis: a meta-analysis","volume":"40","author":"Liu","year":"2017","journal-title":"Clin. Investig. Med."},{"issue":"5","key":"10.1016\/j.ijsu.2019.03.004_bib11","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/jbmr.3384","article-title":"Effects of teriparatide compared with risedronate on the risk of fractures in subgroups of postmenopausal women with severe osteoporosis: the VERO trial","volume":"33","author":"Geusens","year":"2018","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"10.1016\/j.ijsu.2019.03.004_bib12","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann. Intern. Med."},{"issue":"7650","key":"10.1016\/j.ijsu.2019.03.004_bib13","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"Br. Med. J."},{"issue":"6","key":"10.1016\/j.ijsu.2019.03.004_bib14","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/j.1742-1241.2008.01768.x","article-title":"Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial","volume":"62","author":"Anastasilakis","year":"2008","journal-title":"Int. J. Clin. Pract."},{"issue":"7","key":"10.1016\/j.ijsu.2019.03.004_bib15","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1359\/JBMR.050309","article-title":"Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters","volume":"20","author":"Arlot","year":"2005","journal-title":"J. Bone Miner. Res."},{"issue":"10","key":"10.1016\/j.ijsu.2019.03.004_bib16","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1210\/jc.2002-020334","article-title":"A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis","volume":"87","author":"Body","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.ijsu.2019.03.004_bib17","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/jbmr.238","article-title":"Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis","volume":"26","author":"Cosman","year":"2011","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"10.1016\/j.ijsu.2019.03.004_bib18","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1210\/jc.2009-1703","article-title":"Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis","volume":"95","author":"Finkelstein","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.ijsu.2019.03.004_bib19","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s00198-011-1856-y","article-title":"The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures","volume":"23","author":"Hadji","year":"2012","journal-title":"Osteoporos. Int."},{"issue":"1","key":"10.1016\/j.ijsu.2019.03.004_bib20","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1359\/jbmr.061011","article-title":"Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis","volume":"22","author":"Keaveny","year":"2007","journal-title":"J. Bone Miner. Res."},{"issue":"10117","key":"10.1016\/j.ijsu.2019.03.004_bib21","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2017","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.ijsu.2019.03.004_bib22","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1001\/archinte.165.15.1762","article-title":"Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass","volume":"165","author":"McClung","year":"2005","journal-title":"Arch. Intern. Med."},{"issue":"8","key":"10.1016\/j.ijsu.2019.03.004_bib23","first-page":"Cr442","article-title":"Teriparatide vs. alendronate as a treatment for osteoporosis: changes in biochemical markers of bone turnover, BMD and quality of life","volume":"17","author":"Panico","year":"2011","journal-title":"Med. Sci. Mon. Int. Med. J. Exp. Clin. Res."},{"issue":"21","key":"10.1016\/j.ijsu.2019.03.004_bib24","article-title":"Effects of teriparatide versus alendronate for treatment of postmenopausal osteoporosis: a meta-analysis of randomized controlled trials","volume":"96","author":"Wang","year":"2017","journal-title":"Medicine (Baltim.)"},{"issue":"2","key":"10.1016\/j.ijsu.2019.03.004_bib25","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00198-005-2013-2","article-title":"Reduced risk of back pain following teriparatide treatment: a meta-analysis","volume":"17","author":"Nevitt","year":"2006","journal-title":"Osteoporos. Int."},{"issue":"6","key":"10.1016\/j.ijsu.2019.03.004_bib26","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1210\/jc.2011-3060","article-title":"Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis","volume":"97","author":"Murad","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"12","key":"10.1016\/j.ijsu.2019.03.004_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0168691","article-title":"Effectiveness of teriparatide on fracture healing: a systematic review and meta-analysis","volume":"11","author":"Shi","year":"2016","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.ijsu.2019.03.004_bib28","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1172\/JCI91699","article-title":"Parathyroid hormone regulates fates of murine osteoblast precursors in vivo","volume":"127","author":"Balani","year":"2017","journal-title":"J. Clin. Investig."},{"issue":"2","key":"10.1016\/j.ijsu.2019.03.004_bib29","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1742-1241.2011.02837.x","article-title":"Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials","volume":"66","author":"Han","year":"2012","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.ijsu.2019.03.004_bib30","first-page":"2624","article-title":"Single and combined use of human parathyroid hormone (PTH) (1-34) on areal bone mineral density (aBMD) in postmenopausal women with osteoporosis: evidence based on 9 RCTs","volume":"20","author":"Song","year":"2014","journal-title":"Med. Sci. Mon. Int. Med. J. Exp. Clin. Res."},{"issue":"19","key":"10.1016\/j.ijsu.2019.03.004_bib31","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N. Engl. J. Med."}],"container-title":["International Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743919119300597?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743919119300597?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T16:04:52Z","timestamp":1677081892000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1743919119300597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":31,"alternative-id":["S1743919119300597"],"URL":"https:\/\/doi.org\/10.1016\/j.ijsu.2019.03.004","relation":{},"ISSN":["1743-9191"],"issn-type":[{"value":"1743-9191","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Teriparatide versus bisphosphonates for treatment of postmenopausal osteoporosis: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijsu.2019.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd.","name":"copyright","label":"Copyright"}]}}